-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
MIV-150
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/231957-54-3.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 231957-54-3 |
| Description | MIV-150 is an allosteric inhibitor of HIV-1 and HIV-2 reverse transcriptase with both EC50 values of 1 nM in vitro. |
Product Information
| Synonyms | PC-815; 1-(5-cyanopyridin-2-yl)-3-[(1S,2S)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea |
| Molecular Weight | 368.4 |
| Molecular Formula | C19H17FN4O3 |
| Canonical SMILES | CCC(=O)C1=C(C(=C(C=C1)F)C2CC2NC(=O)NC3=NC=C(C=C3)C#N)O |
| InChI | InChI=1S/C19H17FN4O3/c1-2-15(25)11-4-5-13(20)17(18(11)26)12-7-14(12)23-19(27)24-16-6-3-10(8-21)9-22-16/h3-6,9,12,14,26H,2,7H2,1H3,(H2,22,23,24,27)/t12-,14+/m1/s1 |
| InChIKey | NKPHEWJJTGPRSL-OCCSQVGLSA-N |
| Purity | ≥98% |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | Crystalline Solid |
| Storage | Store at -20°C |
| Complexity | 621 |
| Exact Mass | 368.12846858 |
| In Vitro | The activity of MIV-150 to protect target cells from infection is assayed using a syncytial assay. The EC50 of MIV-150 against HIV-1MN in CEM.SS cells is below 1 nM. These data are in agreement with the findings of Medivir. MIV-150 effectively inactivated free virus with an EC50 of 0.004 μg/mL (or 0.01 μM). It is demonstrated MIV-150 is highly effective against HIV and that the drug blocks viruses that are resistant to other marketed HIV antiretrovirals such as Nevirapine, Delavirdine, and Efavirenz. In addition, resistance to MIV-150 develops more slowly than to other anti-HIV drugs tested. For example, in vitro studies demonstrate that resistance development in the presence of nevirapine and delavirdine takes only 4 to 5 weeks compared with 45 weeks in the presence of MIV-150. |
| PSA | 121.83000 |
| Target | HIV-1: <1 nM (EC50) HIV-2: <1 nM (EC50) |
| XLogP3-AA | 2.3 |
